Cardio Diagnostics Holdings (CDIO) Return on Capital Employed (2022 - 2026)
Cardio Diagnostics Holdings (CDIO) posted Return on Capital Employed of 81.24% for Q1 2026, up 3.87% sequentially from 84.51% in Q4 2025, and down 2771.0% YoY from 3.04% in Q1 2025.
Cardio Diagnostics Holdings (CDIO) Return on Capital Employed (2022 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported Return on Capital Employed for 5 years, with the latest figure at 81.24% in Q1 2026.
- Quarterly Return on Capital Employed fell 2771.0% year-over-year to 81.24% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 81.24% (down 2771.0% YoY) and the FY2025 annual result came in at 75.52%, up 4560.0% from the prior year.
- Return on Capital Employed rose to 81.24% in Q1 2026 per CDIO's latest filing, from 84.51% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 1.13% in Q1 2022 and troughed at 261.43% in Q1 2024.
- A 5-year average of 105.89% and a median of 81.24% in 2026 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2025: Return on Capital Employed slumped 23369 bps in 2023, then soared 20791 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 13.33% in 2022, then tumbled by 1143 bps to 165.67% in 2023, then rose by 27 bps to 120.95% in 2024, then jumped by 30 bps to 84.51% in 2025, then advanced by 4 bps to 81.24% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 81.24%, 84.51%, and 71.1% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 7.88% |
| 10 | Cardio Diagnostics Holdings | 6.07 Mn | 483,174.27 | - | -77.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -77.03% |
| Mar 31, 2026 | -81.24% |
| Dec 31, 2025 | -84.51% |
| Sep 30, 2025 | -71.10% |
| Jun 30, 2025 | -56.83% |
| Mar 31, 2025 | -53.52% |
| Dec 31, 2024 | -120.95% |
| Sep 30, 2024 | -213.50% |
| Jun 30, 2024 | -222.57% |
| Mar 31, 2024 | -261.43% |
| Dec 31, 2023 | -165.67% |
| Sep 30, 2023 | -237.25% |
| Dec 31, 2022 | -13.33% |
| Sep 30, 2022 | -3.56% |
| Jun 30, 2022 | -1.78% |
| Mar 31, 2022 | -1.13% |